xMAP® SARS-CoV-2 Multi-Antigen IgG Assay (RUO)
The xMAP® SARS-CoV-2 Multi-Antigen IgG Assay is a serological, multiplexed microsphere-based assay to measure the presence of IgG antibodies directed against the nucleocapsid protein (N), Receptor-Binding Domain (RBD) of the spike protein, and the S1 subunit of the spike protein (S1) of SARS-CoV-2 in human serum or plasma. The xMAP SARS-CoV-2 Multi-Antigen IgG Assay features: Broad Coverage: Detects IgG antibodies aga…
The supplier does not provide quotations for this product through SelectScience. You can search for similar products in our Product Directory.
The xMAP® SARS-CoV-2 Multi-Antigen IgG Assay is a serological, multiplexed microsphere-based assay to measure the presence of IgG antibodies directed against the nucleocapsid protein (N), Receptor-Binding Domain (RBD) of the spike protein, and the S1 subunit of the spike protein (S1) of SARS-CoV-2 in human serum or plasma.
The xMAP SARS-CoV-2 Multi-Antigen IgG Assay features:
- Broad Coverage: Detects IgG antibodies against 3 SARS-CoV-2 antigens, providing comprehensive results:
- S1 subunit of the spike protein
- Receptor Binding Domain (RBD) of the spike protein
- Nucleocapsid protein
- Flexible Throughput: Test up to 96 samples per run in less than 3 hours to meet your throughput needs.
- Versatile System Options: Can be used on MAGPIX®, Luminex® 200™, and FLEXMAP 3D® Systems, so you can use the platform that best fits your lab.
- Common Sample Types: Designed for use with plasma and serum samples, eliminating the need to implement additional collection protocols.
For Research Use Only. Not for use in diagnostic procedures.
xMAP technology: A benchmark for serological testing
In this white paper, Luminex outlines the applications and benefits of its xMAP technology for serological analysis. Multiplex serological testing can be particularly useful in a pandemic, as it can simultaneously analyze large numbers of antigens for large-scale screening and has the potential to replace traditional ELISA assays. Here, it is demonstrated that xMAP technology has become an established benchmark for running these multiplex serology tests.
Dynamic serological monitoring of COVID-19 vaccine response in immunocompromised populations
Watch this presentation by Jeffrey Borgia, Director of Rush University Cancer Center Biorepository and Rush Biomarker Development Core, and Associate Professor, Department of Anatomy & Cell Biology, Rush Medical College, titled: Dynamic serological monitoring of COVID-19 vaccine response in immunocompromised populations. This talk was presented at the SelectScience® Virtual Biopharma Summit 2021.
Luminex submits joint SARS-CoV-2 and Flu/RSV Respiratory Panel to FDA
The multi-analyte respiratory panel combines Flu A/B and respiratory syncytial virus (RSV) targets with the SARS-CoV-2 target
Luminex files for emergency use of expanded NxTAG Respiratory Panel test
Syndromic testing will streamline respiratory infection diagnosis as COVID-19 pandemic collides with start of flu season
